We are Stibbe Life Sciences specialists

In an increasingly complex legal environment, we deliver workable and pragmatic solutions that cater to all our clients’ needs.

Life Sciences

We have one the largest IP and life sciences teams in the Benelux with decades of expertise and experience in related areas of law.

We provide a full range of services to companies active in the pharmaceutical, biotechnological, medical device and food sectors. Our activity encompasses both EU and domestic regulations creating practical solutions that work in the short and long term interests of our clients.

We are active in numerous areas such as intellectual property (patents, trademarks, know-how), pricing/reimbursement, parallel imports, clinical trails, distribution, product registration including biosimilars, licences, R&D agreements and advertising. Furthermore, we have a strong litigation practice.

Our regular contact with public authorities and institutions such as the European Commission, the European Medicines Agency and all Benelux medicines agencies, works to benefit our clients’ position and legal strategy. 

We also regularly team with colleagues who specialise in administrative law and EU/competition law to provide coordinated, integrated solutions for our clients.

Subscribe to newsletter

Experience

Market recognition

With its commitment to offering clients the very best legal service, it is no surprise that Stibbe is repeatedly nominated as the top law firm in Belgium.

Who's Who Legal 2013

Its strong international network provides the firm with the perfect positioning for top end cross-border work and complements its lawyers’ deep industry knowledge and quality output.

Who's Who Legal 100 2013

Other specialists

Related news

22.09.2016 NL law
Tax alert: Dutch Government presents the 2017 budget

Trends - On 20 September 2016, the Dutch government presented the 2017 Budget. As part thereof legislative proposals were submitted to Dutch Parliament on the amendment of certain tax laws in the Netherlands. Below, we will summarize some of the rules which are relevant for internationally oriented corporate taxpayers, that will apply as from 1 January 2017. Please note that the summary is based on the current version of the legislative proposal which is still subject to parliamentary approval.

Read more

24.06.2016 BE law
UK’s referendum — its implication on the Unitary Patent System

Trends - Yesterday, on 23rd June 2016, the United Kingdom has decided, through a public referendum, to leave the European Union.  Aside from the many other consequences of this vote, the decision also has a direct impact on the Unitary Patent/Unified Patent Court system because this new system is not open for participation of a non-EU member state.

Read more

25.10.2016 EU law
A cautionary tale - EU merger control rules may apply to pharma pipeline products

Articles - In Case M.7872 – Novartis/GlaxoSmithKline (ofatumumab autoimmune indications), the European Commission claimed jurisdiction under the merger control rules over a transaction by virtue of which a yet to be fully developed biological drug was transferred to a purchaser. In applying the relevant jurisdictional test, the Commission made a series of observations which have far-reaching implications. 

Read more

04.07.2016 BE law
The impact of Brexit on the pharmaceutical industry

Trends - Following the Brexit referendum, the UK should, in principle, notify its decision in the coming months to withdraw from the EU as provided by Article 50 of the Treaty on the European Union. According to Article 50, the Treaties will cease to apply to the UK from the date of entry into force of the withdrawal agreement or, failing that, two years after the notification—unless the European Council, in agreement with the UK, decides to extend this period unanimously.

Read more

21.09.2015 NL law
Voorwaardelijke ontbinding onder de Wwz, Ernstig verwijtbaar handelen werkneemster, Geen vergoeding en ontbinding op termijn van vier dagen

Articles - De werkneemster is op 1 oktober 2013 bij de werkgever, een farmaceutische onderneming, in dienst getreden als rayonmanager. Op 5 juni 2015 heeft de werkgever de werkneemster op staande voet ontslagen wegens het vervalste cv. De werkneemster heeft de vernietigbaarheid van het ontslag ingeroepen. De werkgever verzoekt nu voorwaardelijk ontbinding.

Read more

27.06.2016 BE law
The International Comparative Legal Guide to: Pharmaceutical Advertising 2016 – Belgium Chapter

Articles - ICLG’s International Comparative Legal Guide to: Pharmaceutical Advertising 2016 provides corporate counsel and international practitioners with a comprehensive worldwide legal analysis of pharmaceutical advertising laws and regulations, including advertisements to healthcare professionals, gifts and financial incentives, and so on.

Read more

21.09.2015 NL law
Voorwaardelijke ontbinding onder de Wwz, Ernstig verwijtbaar handelen werkneemster, Geen vergoeding en ontbinding op termijn van vier dagen

Articles - De werkneemster is op 1 oktober 2013 bij de werkgever, een farmaceutische onderneming, in dienst getreden als rayonmanager. Op 5 juni 2015 heeft de werkgever de werkneemster op staande voet ontslagen wegens het vervalste cv. De werkneemster heeft de vernietigbaarheid van het ontslag ingeroepen. De werkgever verzoekt nu voorwaardelijk ontbinding.

Read more

Our website uses cookies: third party analytics cookies to best adapt our website to your needs & cookies to enable social media functionalities. For more information on the use of cookies, please check our Privacy and Cookie Policy. Please note that you can change your cookie opt-ins at any time via your browser settings.

Privacy and Cookie Policy